Directorio

We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.

Participants will first receive the study drug and be closely monitored for safety. In the second part, participants will be randomly assigned to receive either the study drug by injection or the standard treatment by IV. Treatment is given in 28 day cycles and may continue for up to 24 cycles.

We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.

If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.

If you can join this study, you will be assigned to take one or more study medicines. These medicines are called SPY 001, SPY 002, and SPY 003, and some people will take combinations of these medicines. You will take the assigned medicine or medicines for up to 96 weeks. During the study, which lasts about 33 months, you will have around 18 study visits or phone calls. At these visits, doctors will do tests such as blood draws, heart tests, and procedures like endoscopy to check your health and how the treatment is working.

We are doing this study to find out if the Nectero EAST System® (the study procedure) is a safe and effective option for treating abdominal aortic aneurysms that are small to medium in size.